Kronos Bio Stock Performance
| KRON Stock | USD 0.99 0.02 1.98% |
Kronos Bio has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.0407, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Kronos Bio are expected to decrease at a much lower rate. During the bear market, Kronos Bio is likely to outperform the market. Kronos Bio right now secures a risk of 3.5%. Please verify Kronos Bio maximum drawdown and the relationship between the expected short fall and period momentum indicator , to decide if Kronos Bio will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Kronos Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Kronos Bio may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
Last Split Factor 3:2 | Last Split Date 2003-11-03 |
1 | Kronos Worldwide Inc Shares Up 4.08 percent on Nov 4 | 11/04/2024 |
2 | Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 | 11/14/2024 |
3 | Kronos Bio stock in focus on CEO change, layoffs | 11/27/2024 |
4 | Acquisition by Ridloff Elena of 17000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | 11/29/2024 |
5 | Kronos Worldwide Shares Gap Down Heres Why | 12/04/2024 |
6 | Kronos Worldwide Inc. The Small Cap Chemical Stock Hedge Funds Are Watching Closely | 12/13/2024 |
7 | Kronos Bio Stock Price Down 1.8 percent - Time to Sell - MarketBeat | 12/31/2024 |
8 | We Think Kronos Bio Needs To Drive Business Growth Carefully | 01/13/2025 |
| Begin Period Cash Flow | 78 M |
Kronos |
Kronos Bio Relative Risk vs. Return Landscape
If you would invest 96.00 in Kronos Bio on October 20, 2024 and sell it today you would earn a total of 3.00 from holding Kronos Bio or generate 3.13% return on investment over 90 days. Kronos Bio is currently generating 0.1097% in daily expected returns and assumes 3.5022% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Kronos, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kronos Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kronos Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kronos Bio, and traders can use it to determine the average amount a Kronos Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0313
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | KRON | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.5 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Kronos Bio is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kronos Bio by adding it to a well-diversified portfolio.
Kronos Bio Fundamentals Growth
Kronos Stock prices reflect investors' perceptions of the future prospects and financial health of Kronos Bio, and Kronos Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kronos Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.49) % | ||||
| Current Valuation | (38.11 M) | ||||
| Shares Outstanding | 60.34 M | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 7.24 X | ||||
| Revenue | 6.29 M | ||||
| Gross Profit | 8.41 M | ||||
| EBITDA | (119.69 M) | ||||
| Net Income | (112.67 M) | ||||
| Cash And Equivalents | 267.89 M | ||||
| Cash Per Share | 4.72 X | ||||
| Total Debt | 28.27 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 15.07 X | ||||
| Book Value Per Share | 2.70 X | ||||
| Cash Flow From Operations | (78.58 M) | ||||
| Earnings Per Share | (1.40) X | ||||
| Market Capitalization | 60.94 M | ||||
| Total Asset | 213.28 M | ||||
| Retained Earnings | (508.86 M) | ||||
| Working Capital | 154.08 M | ||||
About Kronos Bio Performance
By examining Kronos Bio's fundamental ratios, stakeholders can obtain critical insights into Kronos Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Kronos Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (760.64) | (798.67) | |
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.81) | (0.77) |
Things to note about Kronos Bio performance evaluation
Checking the ongoing alerts about Kronos Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kronos Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kronos Bio has some characteristics of a very speculative penny stock | |
| Kronos Bio had very high historical volatility over the last 90 days | |
| Kronos Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.29 M. Net Loss for the year was (112.67 M) with profit before overhead, payroll, taxes, and interest of 8.41 M. | |
| Kronos Bio currently holds about 267.89 M in cash with (78.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kronos Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: We Think Kronos Bio Needs To Drive Business Growth Carefully |
- Analyzing Kronos Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kronos Bio's stock is overvalued or undervalued compared to its peers.
- Examining Kronos Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kronos Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kronos Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kronos Bio's stock. These opinions can provide insight into Kronos Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share | Quarterly Revenue Growth 0.442 | Return On Assets | Return On Equity |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.